Name | Title | Contact Details |
---|
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for five additional years of QIDP market exclusivity in the event of U.S. approval. It is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.
Athenix Corp. is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development. In addition, we have leveraged our earlier stage drug discovery and development capabilities to establish multiple partnerships and collaborations with leading pharmaceutical and biopharmaceutical partners. These alliances are designed to advance the development of multiple Exelixis-discovered therapies, and allow Exelixis to focus on maximizing the potential of cabozantinib. Exelixis has worldwide rights to cabozantinib, which we believe could have the potential to treat a wide variety of cancers. Cabozantinib received its initial regulatory approval for a single indication in 2012, and is marketed for that indication under the trade name COMETRIQ®. Cabozantinib is also the subject of a broad, global clinical development program that includes approximately 45 ongoing or planned clinical trials. Exelixis is the sponsor of two active global, randomized phase 3 pivotal trials: the METEOR trial in metastatic renal cell carcinoma, for which positive top-line results were announced in July 2015, and the CELESTIAL trial in advanced hepatocellular carcinoma. Founded and incorporated in 1994, Exelixis is headquartered in South San Francisco, California. We are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer.
Hohenstein Institute America, Inc is a Elon, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.